Skip to main content

Heart Failure - Use of ACE Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Therapy

CBE ID
0610
1.4 Project
National Voluntary Consensus Standards For Clinically Enriched Administrative Data
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Full Year 2009
Is Under Review
No
1.3 Measure Description

The percentage of patients aged 18 and older with Heart Failure who are on an ACEI or ARB

    • 1.14 Numerator

      Patients with a current fill for an ACEI or ARB

    • 1.15 Denominator

      All patients, aged 18 years and older, with a diagnosis of heart failure

    • Exclusions

      Contraindications to an ACEI or ARB, including:
      - Hyperpotassemia
      - Hypertrophic cardiomyopathy
      - Aortic stenosis
      - Hypotension
      - Pregnancy
      - Chronic kidney disease stage 3 and 4
      - Chronic kidney disease stage 5 in the absence of dialysis
      - Hydralazine after prior ACE-I/ARB use
      - 20% increase in creatinine
      - Aliskerin
      - Multiple myeloma
      - Patient data indicating that the member is planning pregnancy
      Additional denominator exclusions:
      - Heart transplant
      - Pulmonary hypertension treatment
      - Valve surgery
      - Patient or provider feedback indicating allergy, intolerance or contraindication




      General exclusions:
      - Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
      - Patients who have been in a skilled nursing facility in the last 3 months

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed National Voluntary Consensus Standards For Clinically Enriched Administrative Data
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      ActiveHealth Management
      Steward Organization POC Email
      [email protected]